10-K Decoder · All companies

Avalo Therapeutics, Inc.

AVTX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$60K$440K−86.4%
Operating income−$72.9M−$68.5M−6.4%
Net income−$78.3M−$35.1M−123%

Questions

What was Avalo Therapeutics's revenue in FY2025?
$60K in FY2025 (Fiscal year ended Dec 31, 2025), −86.4% vs $440K a year earlier, per its 10-K filed Mar 2026.
Was Avalo Therapeutics profitable in FY2025?
No: net income was −$78.3M and operating income −$72.9M in FY2025.